RNS Number:9632P
Medical Marketing Int'l Group PLC
19 September 2003


FOR IMMEDIATE RELEASE                                          19 SEPTEMBER 2003


                      MEDICAL MARKETING INTERNATIONAL PLC
                                     (MMI)

                      The Annual General Meeting : 2003

Medical Marketing International Group plc (MMI) (LSE:MMG) Cambridge, UK, 19
September 2003: At the Annual General Meeting held today, all resolutions
proposed were duly passed.

Following the meeting, David Best, Executive Chairman made the following
statement:

"2002 was a pivotal year for MMI with significant progress being made in most
parts of the business, thus keeping our foot firmly on the accelerator pedal as
we drive towards becoming a global leader in technology management.

Significant contributions where made by our Bioscience Innovation Centre and the
Bioscience VCT. Importantly, we successfully launched the new fee-earning
services Tek-check, Tek-assist and MTS (Mentored Technical Services) which
provides us with further revenue generating products. There were also major
developments within our portfolio of "bio-babies" which includes Oncosense, a
wholly owned cancer therapeutics subsideray and Viratis, a joint-venture with
King's College London and Queen Mary College London to develop a possible
breakthrough in the treatment of HIV/AIDS.

I am delighted to say that this was further demonstrated by yesterday's
significant announcement with regards to progress in our cancer business
Oncosense and again highlights the future potential within our portfolio of '
biobabies'.

We anticipate further important milestones will be achieved during the remainder
of 2003 and beyond as we continue to look at new strategic opportunities, with
the objective of progressing MMI towards the next stage of its development".

For further information, please contact:

David Best - Executive Chairman
MMI Group                                           Tel: +44 (0)1223 477677
www.mmigroup.co.uk

Lisa Baderoon
Buchanan Communications                             Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMSFFFEUSDSEDU